Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679236 | 0.86 | MEN1 (0.61) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL25529179 | 0.86 | RIPK3 (0.47) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL4817184 | 0.84 | MAPK1 (0.51) | ALDH1A1KDM4ELMNAKMT2ANR4A2 | |
| SCHEMBL4993459 | 0.83 | SLC6A2 (0.51) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1137068 | 0.81 | KDM4E (0.54) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1259846 | 0.80 | MYC (0.51) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL20689348 | 0.79 | KMT2A (0.48) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL19284321 | 0.78 | NR4A2 (0.50) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1396731 | 0.78 | MAPK1 (0.58) | ALDH1A1KDM4ELMNASMN1; SMN2MAPT | |
| SCHEMBL4817433 | 0.78 | TSHR (0.56) | ALDH1A1KDM4ELMNAGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | EVOTEC (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| EP-1742948-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | ALDH1A1 2069/4885KDM4E 212/4885LMNA 4358/4885 |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | ALDH1A1 1639/4885KDM4E 2635/4885LMNA 809/4885 |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | ALDH1A1 2213/4885KDM4E 613/4885LMNA 3679/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | ALDH1A1 3939/4885KDM4E 2386/4885LMNA 3709/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | ALDH1A1 1711/4885KDM4E 697/4885LMNA 3582/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | ALDH1A1 2279/4885KDM4E 769/4885LMNA 4731/4885 |
| US-20230203029-A1 | NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF MER TYROSINE KINASE AND AXL TYROSINE KINASE | MERTK, AXL, TYRO3 | ALDH1A1 3238/4885KDM4E 2105/4885LMNA 930/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | ALDH1A1 2279/4885KDM4E 769/4885LMNA 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.